A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma - Wikidata - wikimedia - TriplyDB

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

http://www.wikidata.org/entity/Q28254924

about

Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia Bendamustine for patients with B cell lymphoid malignancies Intensive therapies for mantle cell lymphoma: time for a disease-specific approach?Bortezomib for the treatment of mantle cell lymphoma: an update The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma Next-generation prognostic assessment for diffuse large B-cell lymphoma Risk factors for etiology and prognosis of mantle cell lymphoma Consolidative autologous hematopoietic stem-cell transplantation in first remission for non-Hodgkin lymphoma: current indications and future perspective Management of mantle cell lymphoma in the elderly patient Targeting CD19 in B-cell lymphoma: emerging role of SAR3419 Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents Next-generation surveillance strategies for patients with lymphoma Outcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature review Mantle cell lymphoma: observation to transplantation The European Hematology Association Roadmap for European Hematology Research: a consensus document Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.Current and emerging therapies in mantle cell lymphoma.A systematic approach to the diagnosis of suspected central nervous system lymphoma.Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Databa Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma A balanced hazard ratio for risk group evaluation from survival data.The Danish National Lymphoma Registry: Coverage and Data Quality Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma.First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from th Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study Indian Council of Medical Research Consensus Document for the Management of Non-Hodgkin's Lymphoma (High Grade).Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.Mantle cell lymphoma: a clinically heterogeneous disease in need of tailored approaches.Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.Survival of hematological patients after discharge from the intensive care unit: a prospective observational study.microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.Cytoplasmic expression of C-MYC protein is associated with risk stratification of mantle cell lymphoma.Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

P2860

Q24200280-0E4DE3BE-FFD4-4528-A995-D8BCCDA5D17E Q24236426-B2E10200-D490-4B7E-A080-08DC427EC4F0 Q24299054-A55EC4A2-7AB7-4048-A22C-7DD51EEA3E40 Q26738940-53796A7D-7230-408D-B07B-D2C6C502B51D Q26772907-8AFF0188-DF83-4221-A052-DF8E62737E9A Q26779612-8DF641AB-F41E-4C9F-98AD-24A157FC23A7 Q26796428-F0C25B1C-14B0-4CCD-A65D-3C57228C3309 Q26858960-2D817DE9-FBFC-40F2-97ED-14214331649B Q26998446-2B2F7D93-831B-49A9-A2F6-9F86264A8C2B Q26999395-F03239EE-0EC9-4D00-B393-F8786F5FAC73 Q27027562-AE9FD5B3-A4BB-46DC-9B7D-4603730F2CA1 Q28066710-223CC831-A5EC-461A-AF62-0F35BBB5E0F0 Q28075606-4D16BAF1-8C33-401E-93AB-5DB3BBA122DD Q28084956-AF0D7E47-085B-4824-AB82-9C6E97ACBC49 Q28087748-EEF19BFC-035A-4085-8CB6-58B8AC4D2025 Q28256317-01056370-CDEF-47A7-9617-E818BE3AFA7B Q28830861-E7A9CFEB-8A95-40C8-BE27-CC71ABE8A4DF Q30358639-A9888E22-1606-4445-A84A-94581765FEDA Q30456436-138C6DE4-0130-425A-9B71-C51E9587A42B Q30456545-2C7BC974-CCDF-402E-8745-4B89501613B6 Q30586022-EECC5B22-04FB-4FA4-B599-E1D2124EB976 Q30649483-77877ADD-9ADD-4C84-BACB-CC2226F8031D Q30670674-1300EFE5-8ED0-4E34-B37C-89172504F88F Q30937026-4FCF2175-81C0-43A6-A9D6-1F4FABE8736B Q31110238-D0454A79-F91A-423E-9BDC-71DAAE11A7DA Q33388563-4B2B1FA1-BC6D-4145-B0F4-BF33FC4BC3E4 Q33394153-CE040E28-C28B-4C96-BB33-714BC24A1B89 Q33394873-6E2BC9A8-4226-4184-819C-B928248B7AAB Q33408270-2D23938E-DD84-400E-A4DD-9EC505974438 Q33572807-D75BD738-3430-4143-ACEE-D93386D69DF3 Q33583302-89F6D262-B44C-4521-B1B5-C175CBC810AC Q33585255-4903CB0F-7DBA-4762-8BE7-A83598A6AAA8 Q33586239-1D8B4CED-3CA5-47EE-9240-9E3F66D1F23D Q33627721-F9F3B1F9-B2B1-42D1-BA51-3FE57AD2A428 Q33752015-62199173-64FB-402C-9229-5E647ABD4B56 Q33780259-97CDB346-0CD2-4977-9440-49B510E59556 Q33800959-DA613E2C-C694-4630-B3B3-79716881F6BD Q33802505-29DC9195-7E25-4406-BACB-D601894C78E2 Q33816002-31A98CDA-2BA9-4201-A16F-3E811720A5D9 Q34037828-F6FF5D0E-51DE-4F76-AD43-44A5D4528169

P2860

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

http://www.wikidata.org/entity/Q28254924

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@ast

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@en

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@nl

type

label

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@ast

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@en

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@nl

prefLabel

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@ast

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@en

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@nl

P1433

Q28254924-D2283662-9D98-4EFB-BBE3-3BC988DCC717

P1476

Q28254924-40B57CF4-2688-4B2C-9691-9777230685FF

P2093

Q28254924-073D10DC-7276-45F8-A9AF-8CF6FD3E5B23

Q28254924-1FB3A996-7EAF-4B8A-888A-5CE9169716CD

Q28254924-2A2100B4-C3B7-4543-847B-9955D93F1B92

Q28254924-3139D649-DCFC-4E08-AB13-64876EF6C2B4

Q28254924-39BDE641-7779-49C4-85E8-038F9FA9D752

Q28254924-44275B57-06FA-4A02-BE84-D754F0864313

Q28254924-477CAD7D-7AE1-45C8-86E9-6582CDA4EC3A

Q28254924-48EAEDE7-BBA8-4536-82A5-07008F1AC865

Q28254924-4A207659-7D12-48D6-922D-3F3D2A6CEB61

Q28254924-537185AC-1B06-40C6-8132-CB57BA80C9D7

P304

Q28254924-F40BB5DD-6EA4-4921-B615-7DC9AA4EF36F

P31

Q28254924-4DB1C670-38E8-49EB-9FFD-5F00613BB71F

P3181

Q28254924-83F04492-A97D-44CA-B503-7A4BCB7DBF61

P356

Q28254924-AF2BAF6E-CF7B-4F72-8DE1-14D87233DA72

P407

Q28254924-1D905DA6-8BD8-4123-B6EB-46862F71C3EA

P433

Q28254924-E3801DDC-6056-4966-8F14-F960388E34DB

P478

Q28254924-48ADD8AD-3B3B-4E25-88A0-3C5E9FEE2989

P50

Q28254924-D8631D13-91AD-4D6C-8B15-90050C00B48C

Q28254924-E6C30414-44B4-469D-86E5-527A5A26DA9D

Q28254924-EF4599E0-4D0B-422B-93F9-162EBD75C8BC

P577

Q28254924-A8615836-3873-425F-8E9A-E7A2C3DD2364

P5875

Q28254924-81086FDB-144F-4128-94C7-D7F70E471DA9

P698

Q28254924-67BC212B-CC9B-4701-A091-FCE27B764B3E

P3181

P356

BLOOD-2007-06-095331

P1433

P1476

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

@en

P2093

Achiel van Hoof

http://www.w3.org/2001/XMLSchema#string

Bernd Metzner

http://www.w3.org/2001/XMLSchema#string

Bernhard Wörmann

http://www.w3.org/2001/XMLSchema#string

Christian Gisselbrecht

http://www.w3.org/2001/XMLSchema#string

European Mantle Cell Lymphoma Network

http://www.w3.org/2001/XMLSchema#string

German Low Grade Lymphoma Study Group (GLSG)

http://www.w3.org/2001/XMLSchema#string

Hannes Wandt

http://www.w3.org/2001/XMLSchema#string

Hartmut Eimermacher

http://www.w3.org/2001/XMLSchema#string

Joerg Hasford

http://www.w3.org/2001/XMLSchema#string

Marcel Reiser

http://www.w3.org/2001/XMLSchema#string

P304

558-565

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

537896

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2007-06-095331

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

Hermann Einsele

Hanneke C Kluin-Nelemans

P577

2007-10-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5882500

http://www.w3.org/2001/XMLSchema#string

P698

17962512

http://www.w3.org/2001/XMLSchema#string